Adi Kidron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Adi Kidron has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Diti Machnes Maayan
The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv 52621, Israel
1 shared publication - Irena Offengenden
The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv 52621, Israel
1 shared publication - Liraz Olmer
Bio-Statistical and Bio-Mathematical Unit, The Gertner Institute of Epidemiology and Health Policy Research, Sheba Medical Center, Tel Aviv 52621, Israel
1 shared publication - Mona Kidon
Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel
1 shared publication - Nancy Agmon-Levin
The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv 52621, Israel
1 shared publication - Ramit Maoz-Segal
The Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel
1 shared publication
Latest Publications
- Open Access
Eosinophilia and Risk of Thrombosis and Mortality in Hospitalized Patients: A Retrospective Cohort Study
Background: Eosinophilia, defined as peripheral blood eosinophil counts > 0.5 K/μL, is associated with various clinical conditions, including allergic, infectious, and malignant diseases. Emerging evidence suggests that eosinophils may contribute to thrombo-inflammatory processes, but their association with thromboembolic events and mortality remains insufficiently characterized. This study aimed to evaluate whether eosinophilia is independently associated with increased risk of thromboembolic events and mortality in hospitalized patients. Methods: We conducted a retrospective cohort study using electronic medical records from Sheba Medical Center (2011–2020). Eosinophilia was classified as mild (0.5–1.5 K/μL) or hypereosinophilia (HE, >1.5 K/μL). Patients with eosinophilia were matched 1:1 to controls with normal eosinophil counts based on age, sex, and follow-up duration. Results: Among 93,320 patients (46,660 with eosinophilia and 46,660 controls), thromboembolic events occurred in 20.9% of eosinophilic patients vs. 9.8% of controls. Eosinophilia was independently associated with thrombosis (OR = 1.33; 95% CI, 1.28–1.38; p < 0.0001), with increased risk from counts ≥ 0.7 K/μL. Mortality was also higher among eosinophilic patients (HR = 1.17; 95% CI, 1.13–1.20; p < 0.0001). Conclusions: Eosinophilia is associated with increased thromboembolic and mortality risk, highlighting the importance of eosinophil monitoring in clinical practice.
Open AccessEosinophilia and Risk of Thrombosis and Mortality in Hospitalized Patients: A Retrospective Cohort Study
Background: Eosinophilia, defined as peripheral blood eosinophil counts > 0.5 K/μL, is associated with various clinical conditions, including allergic, infectious, and malignant diseases. Emerging evidence suggests that eosinophils may contribute to thrombo-inflammatory processes, but their association with thromboembolic events and mortality remains insufficiently characterized. This study aimed to evaluate whether eosinophilia is independently associated with increased risk of thromboembolic events and mortality in hospitalized patients. Methods: We conducted a retrospective cohort study using electronic medical records from Sheba Medical Center (2011–2020). Eosinophilia was classified as mild (0.5–1.5 K/μL) or hypereosinophilia (HE, >1.5 K/μL). Patients with eosinophilia were matched 1:1 to controls with normal eosinophil counts based on age, sex, and follow-up duration. Results: Among 93,320 patients (46,660 with eosinophilia and 46,660 controls), thromboembolic events occurred in 20.9% of eosinophilic patients vs. 9.8% of controls. Eosinophilia was independently associated with thrombosis (OR = 1.33; 95% CI, 1.28–1.38; p < 0.0001), with increased risk from counts ≥ 0.7 K/μL. Mortality was also higher among eosinophilic patients (HR = 1.17; 95% CI, 1.13–1.20; p < 0.0001). Conclusions: Eosinophilia is associated with increased thromboembolic and mortality risk, highlighting the importance of eosinophil monitoring in clinical practice.